Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Yahoo Finance • 10 hours ago

Alnylam drops as AstraZeneca posts full trial results for failed heart drug

[Alnylam Pharmaceuticals, Inc.] hapabapa/iStock Editorial via Getty Images AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) on Friday released full data from a failed Phase 3 trial for its RNA-targeting silencer Wainua, developed w... Full story

Yahoo Finance • 10 hours ago

Alnylam stock drops on rival heart trial: Why analysts see core business safe

Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell o... Full story

Yahoo Finance • 2 days ago

Moderna Stock Carries A Market Value Its Revenue Does Not Support

Photo by geralt on Pixabay Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue. Moderna (MRNA) has returned about 486% over the trailing twelve months... Full story

Yahoo Finance • 3 days ago

BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

BridgeBio Pharma BBIO entered the second half of 2026 with Attruby doing most of the commercial heavy lifting. Second-quarter revenues rose 120% year over year and topped the Zacks Consensus Estimate, but the company still posted a wider-t... Full story

Yahoo Finance • 3 days ago

Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?

BridgeBio Pharma BBIO is entering a pivotal commercial stretch. Attruby is scaling quickly, while three late-stage candidates could widen the company's revenue base over the next year. The trade-off is a demanding valuation alongside cont... Full story

Yahoo Finance • 3 days ago

Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

BridgeBio Pharma BBIO shares have gained 24% in the past three months, far ahead of the S&P 500's 0.7% rise over the same period. The move leaves investors weighing whether improving commercial and pipeline momentum can support further gai... Full story

Yahoo Finance • 4 days ago

Alnylam Pharmaceuticals (ALNY) Heads To ESC With New Data, Is It A Bargain?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Alnylam Pharmaceuticals (ALNY) has drawn market attention after announcing plans to present new clinical and real-worl... Full story

Yahoo Finance • 17 days ago

Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks

The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has not been limited to just a handful of companies either, with most S&P 500 sectors contribut... Full story

Yahoo Finance • 24 days ago

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Alnylam (ALNY) To Contact Them Directly To Discuss Their Options If you purchased or acquired stock in Alnylam... Full story

Yahoo Finance • 24 days ago

Securities Fraud Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ... Full story

Yahoo Finance • 24 days ago

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation

BENSALEM, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possibl... Full story

Yahoo Finance • 28 days ago

ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). The investigation concerns whether the C... Full story

Yahoo Finance • 29 days ago

US Stock Market Today: S&P 500 Futures Inch Higher As Inflation Data Looms

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. The Morning Bull - US Market Morning Update Friday, Jul, 31 2026 US stock futures are pointing higher this morning, with E-mini S... Full story

Yahoo Finance • 29 days ago

Stocks Settle Sharply Higher as Microsoft Leads a Surge in Tech Stocks

The S&P 500 Index ($SPX) (SPY) on Thursday closed up +1.66%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +1.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +3.36%.  September E-mini S&P futures (ESU26) rose +1.65%, and S... Full story

Yahoo Finance • 29 days ago

Alnylam Pharmaceuticals Inc (ALNY) (Q2 2026) Earnings Call Highlights: Amvuttra Surpasses $1 ...

This article first appeared on GuruFocus. Total Global Net Product Revenues: Approximately $1.2 billion, representing 74% growth versus Q2 last year. Global TTR Net Revenues (Amvutra): $1.03 billion in Q2, increasing 13% versus Q1 and 89%... Full story

Yahoo Finance • 29 days ago

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

The S&P 500 Index ($SPX) (SPY) today is up +0.86%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.65%.  September E-mini S&P futures (ESU26) are up +0.84%, and September E-mini... Full story

Yahoo Finance • 29 days ago

Alnylam Falls 29% After Reporting Q2 Results

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) plunged after lowering its full-year TTR revenue guidance, overshadowing strong second-quarter revenue growth and a return to profitability. The stock is currently trading at $204.00, down... Full story

Yahoo Finance • 30 days ago

Alnylam (ALNY) Is Up 6.3% After Showcasing New Alzheimer’s RNAi Data And $1B-Plus Quarterly Revenue

In July 2026, Alnylam Pharmaceuticals presented new clinical data and study designs for its Alzheimer's disease RNAi candidates mivelsiran and ALN-5288 at the Alzheimer's Association International Conference in London, including long-term... Full story

Yahoo Finance • last month

What Happens to Stocks After Joining the Nasdaq-100 (History Has a Clear Answer)

Joining the Nasdaq-100 represents a big milestone, as it includes the biggest non-financial companies on the Nasdaq. The idea is, once a company joins, it may see its share price advance as managers of funds tracking this index buy shares... Full story

Yahoo Finance • last month

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Atlas Healthcare Fund managed by VST Capital, today highlighted a series of early conviction investment decisions that have defined its track record since launch — none more striking than its pos... Full story